MX2019012660A - Metodo para tratar cancer empleando un inhibidor de proteina de linfoma de celulas b 2 (bcl-2) en forma conjunta con una radioinmunoterapia con emision de particulas alfa. - Google Patents
Metodo para tratar cancer empleando un inhibidor de proteina de linfoma de celulas b 2 (bcl-2) en forma conjunta con una radioinmunoterapia con emision de particulas alfa.Info
- Publication number
- MX2019012660A MX2019012660A MX2019012660A MX2019012660A MX2019012660A MX 2019012660 A MX2019012660 A MX 2019012660A MX 2019012660 A MX2019012660 A MX 2019012660A MX 2019012660 A MX2019012660 A MX 2019012660A MX 2019012660 A MX2019012660 A MX 2019012660A
- Authority
- MX
- Mexico
- Prior art keywords
- bcl
- inhibitor
- conjunction
- emitting
- cell
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762491803P | 2017-04-28 | 2017-04-28 | |
| PCT/US2018/029607 WO2018200841A1 (en) | 2017-04-28 | 2018-04-26 | Method for treating cancer using a bcl-2 inhibitor in conjunction with an alpha-emitting radioimmunotherapeutic |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019012660A true MX2019012660A (es) | 2020-07-27 |
Family
ID=63919290
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019012660A MX2019012660A (es) | 2017-04-28 | 2018-04-26 | Metodo para tratar cancer empleando un inhibidor de proteina de linfoma de celulas b 2 (bcl-2) en forma conjunta con una radioinmunoterapia con emision de particulas alfa. |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US11364235B2 (enExample) |
| EP (2) | EP4772537A2 (enExample) |
| JP (4) | JP2020517704A (enExample) |
| CN (1) | CN110612109A (enExample) |
| BR (1) | BR112019022308A2 (enExample) |
| CA (1) | CA3059752A1 (enExample) |
| MX (1) | MX2019012660A (enExample) |
| WO (1) | WO2018200841A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4772537A2 (en) * | 2017-04-28 | 2026-07-08 | Actinium Pharmaceuticals, Inc. | Method for treating cancer using a bcl-2 inhibitor in conjunction with an alpha-emitting radioimmunotherapeutic |
| WO2019094931A1 (en) * | 2017-11-10 | 2019-05-16 | Actinium Pharmaceuticals, Inc. | Combination therapy for treatment of a hematological disease |
| CA3125197A1 (en) * | 2019-01-04 | 2020-07-09 | Actinium Pharmaceuticals, Inc. | Methods for treating cancer using combinations of parp inhibitors and antibody radioconjugates |
| TW202131946A (zh) * | 2020-01-10 | 2021-09-01 | 加拿大商融合製藥公司 | 持續性免疫療法 |
| US20240299600A1 (en) * | 2020-09-08 | 2024-09-12 | Actinium Pharmaceuticals, Inc. | Method for treating acute myeloid leukemia using venetoclax in conjunction with lintuzumab-ac225 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4923985A (en) | 1988-05-25 | 1990-05-08 | The United States Of America As Represented By The Department Of Health & Human Services | Process for synthesizing macrocyclic chelates |
| CA2422291C (en) | 2000-09-15 | 2011-03-08 | Sloan-Kettering Institute For Cancer Research | Targeted alpha particle therapy using actinium-225 conjugates |
| US8487131B2 (en) * | 2009-04-15 | 2013-07-16 | Sanford-Burnham Medical Research Institute | Optically pure apogossypol derivative as pan-active inhibitor of anti-apoptotic B-cell lymphoma/leukemia-2 (BCL-2) |
| US8546399B2 (en) * | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| JP6831777B2 (ja) * | 2014-07-21 | 2021-02-17 | ノバルティス アーゲー | Ｃｄ３３キメラ抗原受容体を使用する癌の処置 |
| US10577417B2 (en) | 2014-09-17 | 2020-03-03 | Novartis Ag | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| US20160113925A1 (en) * | 2014-10-22 | 2016-04-28 | Emory University | Methods of treating cancer with a combination of glucose modulators and bcl-2 inhibitors |
| TW201639573A (zh) * | 2015-02-03 | 2016-11-16 | 吉李德科學股份有限公司 | 有關治療癌症之合併治療 |
| PL3280729T3 (pl) * | 2015-04-08 | 2022-08-22 | Novartis Ag | Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19 |
| WO2017021963A1 (en) * | 2015-08-03 | 2017-02-09 | Biokine Therapeutics Ltd. | Cxcr4 binding agents for treatment of diseases |
| EP4772537A2 (en) * | 2017-04-28 | 2026-07-08 | Actinium Pharmaceuticals, Inc. | Method for treating cancer using a bcl-2 inhibitor in conjunction with an alpha-emitting radioimmunotherapeutic |
-
2018
- 2018-04-26 EP EP26175547.4A patent/EP4772537A2/en active Pending
- 2018-04-26 CA CA3059752A patent/CA3059752A1/en active Pending
- 2018-04-26 BR BR112019022308-8A patent/BR112019022308A2/pt unknown
- 2018-04-26 EP EP18792272.9A patent/EP3615047A4/en active Pending
- 2018-04-26 JP JP2019558417A patent/JP2020517704A/ja not_active Withdrawn
- 2018-04-26 US US16/607,168 patent/US11364235B2/en active Active
- 2018-04-26 WO PCT/US2018/029607 patent/WO2018200841A1/en not_active Ceased
- 2018-04-26 CN CN201880027661.XA patent/CN110612109A/zh active Pending
- 2018-04-26 MX MX2019012660A patent/MX2019012660A/es unknown
-
2020
- 2020-07-03 JP JP2020115411A patent/JP2020158544A/ja not_active Withdrawn
-
2022
- 2022-05-16 US US17/745,045 patent/US11844799B2/en active Active
-
2023
- 2023-09-28 JP JP2023168404A patent/JP2023165952A/ja not_active Withdrawn
- 2023-11-02 US US18/500,735 patent/US12133849B2/en active Active
-
2024
- 2024-09-30 US US18/901,169 patent/US20250017919A1/en active Pending
-
2025
- 2025-11-21 JP JP2025202062A patent/JP2026026133A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3059752A1 (en) | 2018-11-01 |
| CN110612109A (zh) | 2019-12-24 |
| US12133849B2 (en) | 2024-11-05 |
| EP3615047A4 (en) | 2021-01-13 |
| WO2018200841A1 (en) | 2018-11-01 |
| US20220273648A1 (en) | 2022-09-01 |
| JP2020158544A (ja) | 2020-10-01 |
| US20250017919A1 (en) | 2025-01-16 |
| US20240131025A1 (en) | 2024-04-25 |
| US11844799B2 (en) | 2023-12-19 |
| US11364235B2 (en) | 2022-06-21 |
| JP2026026133A (ja) | 2026-02-16 |
| EP3615047A1 (en) | 2020-03-04 |
| US20200383974A1 (en) | 2020-12-10 |
| JP2020517704A (ja) | 2020-06-18 |
| EP4772537A2 (en) | 2026-07-08 |
| JP2023165952A (ja) | 2023-11-17 |
| BR112019022308A2 (pt) | 2020-05-26 |
| US20240226095A9 (en) | 2024-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022006078A (es) | Terapias de combinacion para el tratamiento del cancer. | |
| CO2020015255A2 (es) | Métodos y composiciones para tratar el cáncer | |
| PH12020550936A1 (en) | Combination drug including tlr7 agonist | |
| MX2024000739A (es) | Composiciones y metodos para la inhibicion de antigenos especificos de linaje. | |
| MX2021013225A (es) | Composiciones y metodos para el tratamiento del cancer utilizando una terapia de celulas t modificadas de cd8. | |
| CL2019001874A1 (es) | Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos. | |
| CO2017011197A2 (es) | Terapia de combinación fgfr/pd-1 para el tratamiento del cancer | |
| MX2021014302A (es) | Metodo para tratar la enfermedad inflamatoria del intestino con una terapia de combinacion de anticuerpos contra il-23 y tnf alfa. | |
| CL2021001432A1 (es) | Terapia de combinación de radioinmunoconjugados con inhibidores de daños y reparaciones del adn | |
| MX2020009757A (es) | Producto combinado de inhibidor de bcl-2 e inhibidor de mdm2 y uso de este en la prevencion y/o tratamiento de enfermedades. | |
| MX2020013120A (es) | Tratamiento terapéutico de cánceres de microsatélites inestables. | |
| BR112018067368A2 (pt) | terapia de combinação com anticorpos anti-cd73 | |
| MX2018004599A (es) | Terapia de combinacion para el tratamiento de neoplasias malignas. | |
| MX387363B (es) | Tratamiento de cáncer con una combinación de radiación, nanopartículas de óxido de cerio y un agente quimioterapéutico. | |
| MX2020003947A (es) | Anticuerpo anti-cd3 y composicion farmaceutica para el tratamiento del cancer que comprende el mismo. | |
| MX2016007111A (es) | Inhibidores de tirosina quinasa de bruton. | |
| MX2022008868A (es) | Tratamiento del cancer con tg02. | |
| AR116121A1 (es) | Métodos de tratamiento del cáncer | |
| MX2016012176A (es) | Composiciones y metodos para mejorar los linfocitos infiltrantes de tumor para terapia celular adoptiva. | |
| MX2021006954A (es) | Terapia combinada contra el virus de la hepatitis b (vhb). | |
| MX2017006685A (es) | Tratamiento de enfermedades asociadas con activacion de celulas estrelladas hepaticas usando terapias reductoras de amoniaco. | |
| BR112021022951A2 (pt) | Composições e métodos para o tratamento de doenças mediadas por atpase | |
| UY37800A (es) | AGENTES DE iARN PARA LA INHIBICIÓN DE LA EXPRESIÓN DE ALFA-ENaC Y MÉTODOS DE USO | |
| UY36542A (es) | Formulaciones farmacéuticas para anticuerpos anti-tnf-alfa | |
| MX2018003497A (es) | Formulaciones de aminoacidos de liberacion modificada administradas por via oral. |